Table 5.
Association between statin use and hepatocellular carcinoma
| Study | Region | Etiology | Study design | Patients/HCC cases | Result (95% CI) | P-value |
|---|---|---|---|---|---|---|
| Campbell et al. [17] (2020) | HBV | Meta-analysis | 40 studies (536,456) | HR, 0.36 (0.19–0.68) to HR, 0.81 (0.73–0.90) | ||
| Chen et al. [33] (2015) | Taiwan | HBV | Population-based cohort study | 71,824/1,735 | HR, 0.34 (0.27–0.42) | <0.001 |
| Goh et al. [75] (2020) | Korea | HBV | Retrospective cohort study | 7,713/702 | HR, 0.36 (0.19–0.68) | 0.002 |
| Wu et al. [76] (2014) | Taiwan | HBV | Population-based cohort study | 43,190/5,446 | HR, 0.55 (0.47–0.63) | <0.001 |
| Tsan et al. [87] (2012) | Taiwan | HBV | Population-based cohort study | 33,413/1,021 | HR, 0.47 (0.36–0.61) | <0.001 |
| Hsiang et al. [88] (2015) | China | HBV | Cohort study | 73,499/6,883 | HR, 0.68 (0.48–0.97) | 0.033 |
| Tsan et al. [89] (2013) | Taiwan | HCV | Population-based cohort study | 260,864/27,883 | HR, 0.53 (0.49–0.58) | <0.001 |
| Butt et al. [90] (2015) | USA | HCV | Cohort study | 7,248 | HR, 0.52 (0.35–0.78) | <0.001 |
| Mohanty et al. [91] (2016) | USA | HCV | Retrospective cohort study | 2,747/173 | HR, 0.42 (0.27–0.64) | <0.001 |
| Simon et al. [92] (2016) | USA | HCV | Cohort study | 9,135/239 | HR, 0.85 (0.47–1.53) | 0.580 |
| Li et al. [93] (2020) | HBV, HCV | Meta-analysis | 13 studies (519,707) | RR, 0.54 (0.44–0.66) | <0.001 | |
| Wong et al. [94] (2021) | HBV, HCV, LC | Meta-analysis | 13 studies (1,742,260) | HR, 0.57 (0.52–0.62) | 0.060 | |
| Lee et al. [36] (2017) | Taiwan | NAFLD | Population-based cohort study | 18,080/41 | HR, 0.29 (0.12–0.68) | 0.005 |
HCC, hepatocellular carcinoma; CI, confidence interval; HBV, hepatitis B virus; HR, hazard ratio; HCV, hepatitis C virus; LC, liver cirrhosis; RR, risk ratio; NAFLD, non-alcoholic fatty liver disease.